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Abstract
Amyloidoses represent a highly heterogeneous group of diseases characterized by the
abnormal production and accumulation of abnormal, insoluble amyloid proteins in
various tissues leading to organ dysfunction. Light‐chain (AL) amyloidosis is the most
common form of systemic amyloidosis and is characterized by extracellular deposi‐
tion of pathologic insoluble fibrillar proteins in organs and tissues. Primary systemic
AL amyloidosis (AL) arises from the production of abnormal immunoglobulins (Igs) by
clonal plasma cells, such as those associated with the plasma cell dyscrasia multiple
myeloma (MM). AL amyloidosis can affect a wide range of organs, most commonly the
kidneys, and consequently presents with a range of symptoms. Currently, the most
effective treatment is autologous bone marrow transplants with stem cell rescue, but
many  patients  are  too  weak  to  tolerate  this  approach  and  are  ineligible.  Novel
therapeutic  strategies  recently  used  include  forms  of  chemotherapy  and  targeted
therapy similar to those used to treat MM. As a single agent, the proteasome inhibitor
bortezomib has notable activity in selected populations of patients with relapsed AL.
Here, we discuss recent advances using proteasome inhibitors to improve the outcome
of AL amyloidosis patients.
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1. Introduction
Light‐chain amyloidosis (AL) is a dyscrasia of clonal origin that results in amyloid fibril
deposition within vital organs leading to their progressive dysfunction and ultimately death.
The precise molecular events that lead to AL amyloidosis are poorly understood and treat‐
ment options based upon the biology of disease that improve patient survival are limited. AL
amyloidosis is frequently a challenge to diagnose because of its broad spectrum of symptoms.
Clinical manifestations include nephrotic‐range proteinuria, hepatomegaly, congestive heart
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failure (CHF), and autonomic and sensory neuropathy. Diagnostic advances include develop‐
ment of a serum‐free light‐chain assay, cardiac magnetic resonance imaging (MRI), and serologic
cardiac biomarkers. Treatment advances include the inclusion of the proteasome inhibitor
bortezomib. Here, we discuss current and emerging treatment strategies, many focused on
proteasome inhibitors, that have evolved or are evolving to prolong survival and preserve organ
function in patients with this disease. Finally, we discuss emerging strategies designed to
eradicate the clonal cell of origin that may provide further clinical benefit for AL amyloidosis
patients.
2. Targeting the ubiquitin + proteasome system in AL amyloidosis
Protein degradation is a highly complex, temporally controlled, highly regulated process that
maintains proteostasis in eukaryotic cells [1–5]. In normal and transformed cells, protein
degradation pathways fulfill an essential role to maintain many critical pro‐survival path‐
ways [1]. Studies by Schoenheimer [1] in the 1930s described the dynamic turnover of
individual cellular proteins. Subsequently, it was shown that protein half‐lives required
energy, in the form of ATP, and that the half‐lives of individual proteins varied widely within
mammalian cells2. Previously, the lysosome had been considered the central site of intracel‐
lular proteolysis [3]. Discovery of the small polypeptide protein ubiquitin (Ub) followed as
well as experiments demonstrating that Ub is covalently conjugated to target proteins to direct
their proteasomal degradation then greatly advanced understanding protein degradation
(Figure 1) [4, 5]. Ub is covalently linked to protein targets in three sequential steps to target
proteins to direct their rapid, ATP‐dependent proteasomal degradation. In the first step, Ub
is activated by an enzyme referred to as E1. Ub is then transferred from E1 to an E2 Ub‐
conjugating enzyme, and an isopeptide bond is formed between a lysine residue on the
substrate target and the carboxy‐terminus glycine of the Ub moiety. E3 Ub protein ligases then
recognize Ub‐conjugated target proteins [4, 5].
The vast majority of intracellular proteins are degraded by proteasomes in eukaryotic cells.
The 26S proteasome is high‐molecular‐weight, ATP‐dependent structure that consists of a
20S catalytic core particle (CP) capped at the ends by 19S regulatory particles (RP) (Figure 2)
[6–10]. The proteasome serves as the catalytic core of the Ub‐proteasome system (UPS) to
degrade short‐lived and denatured proteins and was the first component of the Ub‐protea‐
some pathway to be targeted therapeutically. Bortezomib is a selective, boron‐containing
reversible inhibitor of the proteasome that induces apoptosis in a number of different cancer
cells. Bortezomib is a potent small molecule that binds reversibly to the proteasome β‐5 subunit
to inhibit the chymotryptic‐like (Ct‐L) activity (Figure 3). The anti‐tumor effect of bortezo‐
mib was evident in a multitude of cell lines and xenograft models from different cancer
types [11–15], including malignant plasma cells. Bortezomib has demonstrated substantial
benefit in monotherapy or in combinations that induce chemo‐ or radiosensitization [11].
Federal Drug Administration (FDA)‐approval of bortezomib (Velcade, Millennium‐Takeda
Oncology Co., Cambridge, MA) represented a major advance in the treatment of MM [11, 12].
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Bortezomib is the first proteasome inhibitor to change the natural history of a hematologic
malignancy. However, clinical efficacy in the treatment of solid tumors has not been achieved.
Figure 1. Schematic representation of the Ub + proteasome system. The UPS pathway for protein degradation in eu‐
karyotic cells comprises: (1) a series of enzymes [E1, activation; E2, conjugation; E3, ligation] that covalently modify
proteins with a polyubiquitin tag for recognition and targeted degradation and (2) the 26S proteasome, a 2 MDa multi‐
catalytic enzyme complex that hydrolyzes the polyubiquitin‐tagged proteins into short polypeptides, typically seven
to nine amino acids in length. The proteasome degrades unwanted proteins by recognizing specific polyubiquitin tags
covalently attached to these proteins. Inhibition of the proteasome catalytic core by bortezomib leads to the unwanted
accumulation of ubiquitinated proteins and culminates in apoptosis.
Figure 2. Subunit organization of the 26S proteasome. The 26S proteasome is a eukaryotic ATP‐dependent, dumbbell‐
shaped protease complex with a molecular mass of approximately 2000 kDa. It consists of a central 20S proteasome,
functioning as a catalytic machine, and two large V‐shaped terminal modules, having possible regulatory roles, com‐
posed of multiple subunits of 25–110 kDa attached to the central portion in opposite orientations. Shown are the 20S
proteasome catalytic particles (CP) and the 19S regulatory particles (RP). The 19S regulator is bound to either one or
both ends of the 20S proteasome and stimulates hydrolytic activity of the 20S proteasome. The 19S RP enables ATP‐
dependent degradation of ubiquitinated proteins and supports elevated peptidase activity but not ubiquitin‐conjugate
degradation.
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Figure 3. The 20S proteasome CP houses three pairs of catalytically active subunits, β1, β2, and β5, that exhibit protein
substrate cleavage preferences referred to as caspase‐like (C‐L), trypsin‐like (T‐L), and chymotrypsin‐like (CT‐L), re‐
spectively, and which work in concert to degrade protein substrates. Substrate hydrolysis by the 20S CP commences
with recognition of amino acid side chains by sequential binding pockets proximal to the proteolytic active site. Borte‐
zomib forms a reversible, non‐covalent adduct at the active site of the β‐5 subunit. Carfilzomib has irreversible binding
properties for the same active site of the β‐5 subunit. Marizomib is a β‐lactone‐γ‐lactam that binds slowly with sus‐
tained inhibition of the proteasome β‐1, β‐2, and β‐5 active sites.
The aim of current treatment strategies for AL is to inhibit production of insoluble amyloido‐
genic immunoglobulin light‐chain fragments and ultimately restore organ function [16–18].
AL and MM are both clonal plasma cell dyscrasias and, therefore, AL treatment is typically
based on therapies that have shown efficacy in MM [19, 20]. The depth of hematologic response
and complete response (CR) has been linked with improved organ function in AL patients and
improved overall survival (OS) in MM [21–23]. Intensive therapy with high‐dose melphalan
and stem cell transplantation has been shown to be highly effective in AL, but a risk‐adapt‐
ed strategy may be needed to reduce mortality and toxicity [24, 25]. In addition, similar to MM,
side effects with treatment are evident and drug resistance emerges even in patients that do
respond initially.
Second‐generation proteasome inhibitors offer a number of potential advantages over
bortezomib. The newer proteasome inhibitors may provide improved target specificity, safety,
tolerability, and the capacity to overcome bortezomib resistance (Table 1). Second‐genera‐
tion proteasome inhibitors include the recently FDA‐approved epoxyketone carfilzomib [26],
and agents in clinical development that include ONX‐0912 [27], Ixazomib (Ninlaro) [28]
(Millennium‐Takeda), Marizomib [29] (NPI‐0052), and CEP‐18870 [30] (Cephalon). In contrast
to bortezomib, carfilzomib is an irreversible proteasome inhibitor. Ixazomib is an orally
bioavailable reversible proteasome inhibitor that is immediately hydrolyzed to its active form,
MLN2238 after conversion in aqueous solutions. Ixazomib binds preferentially to the protea‐
some β‐5 active site to inhibit the chymotrypsin‐like activity. Ixazomib and CEP‐18770 are
reversible inhibitors of the proteasome Ct‐L activity that exhibit inhibitory activity compara‐
ble to bortezomib. The differences improved anti‐tumor activity.
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Inhibitor  Structural
Class
Inhibitor
Type
inhibited
Activity Stage of
Development
Route of
administration
Bortezomib
(Millennium)
Peptide‐ boronic acid R Ct‐L FDA‐approved
Immuno
IV
Carfilzomib (Onyx) Tetrapeptide
epoxyketone
I Ct‐L FDA‐approved IV
MLN9708
(Millennium
Peptide boronic acid R Ct‐L Phase I IV/po
Marizomib (Nereus) β‐lactone‐ γ‐lactam I Ct‐L, Tryptic,
Caspase‐like
Phase Ib IV
ONX‐0912 (Onyx) Peptide epoxyketone R Ct‐L Phase I IV/po
Cep‐18870
(Cephalon)
Peptide‐ >boronic acid R Ct‐L Phase I–III IV/po
R = reversible, I = irreversible; Ct‐L = chymotryptic‐like; Immuno = immunoproteasome, IV = intravenous; po = oral
Table 1. Agents to target the proteolytic activities within the proteasome complex.
Carfilzomib is a tetrapeptide epoxyketone that also irreversibly inhibits the Ct‐L activity of
proteasomes [31–36]. Carfilzomib yields a more sustained inhibition compared to bortezo‐
mib and has been shown to promote cell death in bortezomib‐resistant cells. ONX‐0912 is an
orally bioavailable analog of carfilzomib that has been investigated in early phase trials to
study the effect on solid tumors. ONX‐0912 irreversibly inhibits β‐5 activity and in xenograft
models was shown to reduce tumor growth and prolong survival. ONX‐0914 is an immuno‐
proteasome‐specific inhibitor with potential to treat both cancers and autoimmune diseases.
Marizomib (NPI‐0052) irreversibly inhibits the β‐5 subunit and is a natural β‐lactone derived
from Salinospora tropica. Marizomib inhibits the major catalytic activities (Ct‐L, tryptic‐like, and
caspase‐like) of proteasomes which may yield a long‐term benefit to preclude resistance
(Figure 3). Thus, the benefit of second‐generation proteasome inhibitors may be due to their
ability to act as irreversible inhibitors and to inhibit multiple active sites within the proteasome.
3. Clinical evaluation of proteasome inhibitors for AL amyloidosis
treatment
Intensive therapy with high‐dose melphalan (a chemotherapy drug belonging to the class of
nitrogen mustard alkylating agents) and stem cell transplantation (SCT) have been com‐
bined as a regimen (MEL‐SCT) and used as an effective therapy in AL amyloidosis. MEL‐SCT
is used as a risk‐adapted approach that is necessary to minimize treatment‐related mortality
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(TRM). Therefore, up to 82% of persons with AL amyloidosis may be ineligible for MEL‐SCT
based upon age, performance status, and severity of cardiac involvement. Wechalekar et al.
[37] reported preliminary observations with bortezomib and demonstrated its effectiveness in
a heavily pre‐treated population, with an 80% hematologic overall response (OR) rate,
including 15% hematologic CR rates. A subsequent phase I/II study of single agent bortezo‐
mib in relapsed/refractory aL amyloidosis showed excellent tolerance to both once‐ and twice‐
weekly [38]. Importantly, the median time to response in the twice‐weekly arm was only 0.7
months. One‐year hematologic response rates were 72.2 and 74.6%, one‐year response rates
were 93.8 and 84.0%, and one‐third of patients exhibited a CR. The median OS was 61.1
months [39]. Rates of neuropathy were as high as 35% in the twice‐weekly, with 9% rate of
discontinuation and 6% rate of dose reductions.
Deregulating the ubiquitin‐proteasome pathway may affect the heart, causing plaque
instability, altered intracellular signal transduction resulting in decreased myocardial
cytoprotection, desensitization of adrenergic receptors, and accumulation of unfolded proteins
impairing cardiac function [40]. Although cardiac toxicity was described in small series, case
reports, and clinical trials, subsequent meta‐analysis did not support an increase in cardio‐
toxicity in multiple myeloma (MM) [41]. Early sudden death has been described in amyloid
cardiomyopathy in persons treated with bortezomib. The Greek and UK groups demonstrat‐
ed increased rates of early cardiac death in those treated with bortezomib, when compared to
lenalidomide [42, 43]. However, sudden death is not uncommon in advanced amyloid
cardiomyopathy. Since bortezomib typically has a shorter time to hematologic response, it is
used more frequently than lenalidomide in advanced cardiac amyloidosis. Therefore,
increased rates of sudden death may be related to patient selection, rather than a class effect
from proteasome inhibitors.
Since bortezomib demonstrated such great promise, several studies explored the clinical
efficacy in triplets, including cyclophosphamide, bortezomib, and dexamethasone (CyBorD).
These retrospective studies reported on 17 and 43 patients, with hematologic response rates
of 81–94% and hematologic CR rates of 39.5–71.5% [44, 45]. At least half of the patients had
symptomatic cardiac involvement and many had a cardiac‐specific response. However, a
retrospective study from the UK demonstrated poorer outcomes than the two aforemen‐
tioned studies [46]. Of 230 patients, a hematologic response rate was 60%, which decreased
to 42% in those with advanced cardiac stage III patients. Cardiac response was achieved in
only 17% of patients. Unfortunately, CyBorD is associated with grade 3 and grade 4 toxici‐
ties in 50% of patients.
Bortezomib has been combined with melphalan and dexamethasone, possibly with more
promising outcomes than CyBorD (Table 2). A prospective, multi‐center phase II trial of
bortezomib, melphalan, and dexamethasone (VMD) in newly diagnosed or relapsed AL
amyloidosis showed hematologic response rates of 94%, with CR of 38%. However, this was
a small trial and 52% of patients required dose reduction despite an excellent performance
status, questioning whether such an impressive response can be replicated off trial [47]. A
subsequent phase I trial demonstrated improved safety and greater tolerability [48]. Using
prospectively collected data, the Pavia group demonstrated higher response rates with VMD,
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when compared to CyBorD (p=0.033) or melphalan/dexamethasone alone (p = 0.010) [49].
While the exposure to upfront bortezomib is associated with longer OS, a difference be‐
tween CyBorD and VMD could not be detected. A bortezomib/dexamethasone backbone is
necessary in persons ineligible for melphalan‐stem cell transplantation (MEL‐SCT), and it is
not clear whether melphalan or cyclophosphamide should be added. The addition of melpha‐
lan is supported with more prospective data, but higher cumulative doses are associated with
leukemia, and melphalan should be avoided in persons who are borderline candidates for
autologous stem cell transplantation.
Regimen Type of
Study
Patients Population
Size
ORR (%)  CR (%) Dose Adjustment/
discontinuation (%)
BD36 Retrospective R/R 18 94 44 61
BD27 Retrospective R/R 20 80 15 40
BD43 Retrospective ND 18 81 47
BD43 Retrospective R/R 76 68 20
BD28 Phase I/II R/R 70 69 37.5 53
CyBorD34 Retrospective ND 17 94 71
CyBorD35 Retrospective ND, R/R 43 81 42
CyBorD36 Retrospective ND 230 60 23
VMD37 Phase I/II ND, R/R 30 94 38 52
VMD38 Phase I/II 9
ID40 Phase I R/R 22 53 11
KD41 Phase I R/R 12 77 0
AL = light chain; ORR = overall response rate; CR = hematologic complete response; BD = bortezomib/dexamethasone;
ND = newly diagnosed; CyBorD = cyclophosphamide/bortezomib/dexamethasone; VMD= bortezomib/melphalan/
dexamethasone; ID= ixazomib/dexamethasone; KD= carfilzomib/dexamethasone
Table 2. Proteasome inhibitors used in treatment regimens for AL amyloidosis.
The use of ixazomib in a phase I study in relapsed/refractory AL amyloidosis was reported
only in abstract form [50]. Of the 22 patients enrolled, 11 patients were previously treated with
bortezomib and 15 with cardiac involvement. Seventy‐seven percent were able to reach
maximum‐tolerated dose. A hematologic response was obtained in 53%, including 11% CR.
An organ‐specific cardiac response was seen in three of nine patients. The 2‐year OS was 57%,
up to 85% in proteasome inhibitor naïve patients. Tourmaline‐AL1, a phase III trial for
ixazomib/dexamethasone vs. physician's choice is currently ongoing and accruing patients.
Carfilzomib is another second‐generation proteasome inhibitor that is being investigated as a
potential treatment in AL amyloidosis. A phase I dose escalation study of carfilzomib in AL
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amyloidosis in a bortezomib‐exposed population enrolled 12 patients [51]. A hematologic OR
rate of 77% was reported and no dose‐related toxicity was noted in carfilzomib doses as high
as 36 mg/m2. However, three significant cardiac events were noted, including ventricular
tachycardia, grade 4 restrictive cardiomyopathy, and a grade 3 drop in the left ventricular
ejection fraction. Although promising, second‐generation proteasome inhibitors may not
provide significant long‐term benefit and overcome therapeutic resistance in refractory
patients. Numerous mechanisms of resistance have been proposed, for example, mutations of
PSMB5, upregulation of other proteasome subunits, alterations of gene and protein expres‐
sion in stress response pathways, induction of autophagy, and an increase in anti‐apoptotic
pathways as well as multidrug resistance pathways. Hence, a number of novel therapeutic
strategies for AL amyloidosis are under development [52, 53]. Currently, treatment choices
remain highly individualized and are dependent on a careful assessment of performance status
and organ function.
4. Targeting the clonal cell of origin as a treatment strategy for AL
amyloidosis
The incidence of AL amyloidosis is similar to that of Hodgkin's lymphoma and chronic
myelogenous leukemia (CML). Approximately 5–12 individuals/million/year are affected,
although autopsy studies suggest a higher incidence. Amyloidosis is a monoclonal plasma cell
disorder in which the secreted monoclonal Ig protein forms insoluble fibrillar deposits in one
or more organs. In nearly all cases, the deposits contain Ig light (L) chains or L‐chain frag‐
ments. AL is related to both MM and monoclonal gammopathy of undetermined signifi‐
cance (MGUS), a pre‐malignant condition that nearly uniformly precedes MM. These
monoclonal plasma cell disorders are categorized according to the total body burden of
monoclonal plasma cells. When this burden is large, the diagnostic criteria for MM are fulfilled;
when this burden is lower, MGUS is diagnosed. The plasma cell burden is typically low at 5–
10%, and in ∼10–15% of patients, AL amyloidosis occurs in association with MM.
5. Concluding remarks
While targeting proteostasis is a highly effective strategy to treat plasma cell dyscrasias such
as AL, more effective agents are needed to improve organ dysfunction and advance patients
to SCT. Moreover, similar to MM, high‐risk forms of disease exist which do not respond to
bortezomib and for those that do respond drug resistance eventually emerges. While the
explosion of novel agents with activity in MM holds promise for the care of patients with AL
amyloidosis, a commitment specifically to the clinical investigation of AL amyloidosis is
needed to improve patient outcomes. Therefore, there is an urgent and unmet need for more
effective therapeutic agents based upon the biology of the disease that increase patient
survival.
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